Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models

@inproceedings{Lee2016EfficacyOT,
  title={Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models},
  author={Michael S. Lee and Timothy L. Helms and Ningping Feng and Jason Gay and Qing Edward Chang and Feng Tian and Ji Yuan Wu and Carlo Toniatti and Timothy Paul Heffernan and Garth Powis and Lawrence N. Kwong and Scott Kopetz},
  booktitle={Oncotarget},
  year={2016}
}
PURPOSE Though the efficacy of MEK inhibitors is being investigated in KRAS-mutant colorectal cancers (CRC), early clinical trials of MEK inhibitor monotherapy did not reveal significant antitumor activity. Resistance to MEK inhibitor monotherapy developed through a variety of mechanisms converging in ERK reactivation. Since ERK increases cyclin D expression and increases entry into the cell cycle, we hypothesized that the combination of MEK inhibitors and CDK4/6 inhibitors would have… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 11 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 72 references

Genomic Classification of Cutaneous Melanoma

  • N CancerGenomeAtlas
  • Cell
  • 2015

Phase II pharmacodynamic trial of palbociclib in patients with KRAS mutant colorectal cancer

  • MH O’Hara, C Edmonds, +10 authors M Gallagher
  • J Clin Oncol
  • 2015

A phase I study of the single-agent CDK4/6 inhibitor LEE011 in pts with advanced solid tumors and lymphomas

  • JR Infante, G Shapiro, +9 authors P. Cassier
  • J Clin Oncol
  • 2014

ADAM17dependent c-MET-STAT3 signaling mediates resistance to MEK inhibitors in KRAS mutant colorectal cancer

  • S Van Schaeybroeck, M Kalimutho, +10 authors HJ Lenz
  • Cell Rep
  • 2014

Similar Papers

Loading similar papers…